IDbyDNA/Illumina RUO Respiratory Pathogen ID/AMR Target Enrichment Panel
IDbyDNA and Illumina this week launched their codeveloped Respiratory Pathogen ID/AMR Target Enrichment Panel for research use only. Developed under a previously announced strategic partnership between the companies, the panel uses IDbyDNA's Explify software platform and Illumina's next-generation sequencing technology to detect more than 280 respiratory pathogens (bacterial, viral, and fungal) as well as genes associated with more than 1,200 antimicrobial resistance markers. Using Illumina's MiniSeq Rapid Reagent Kit, the panel can deliver results in less than 24 hours. IDbyDNA's Explify database includes millions of curated DNA and RNA reference sequences and can identify more than 50,000 microorganisms and more than 6,000 known common and rare pathogens, including antimicrobial resistance.
Caris Life Sciences CODEai
Caris Life Sciences has launched CODEai (Comprehensive Oncology Data Explorer), a real-world clinico-genomic data platform that uses artificial intelligence technology to integrate the company's catalog of molecular data with cancer treatment information and clinical outcomes data for more than 215,000 patients covering more than 1 million data points per patient.
Integrating genomically profiled patient cases with associated treatments and outcomes, CODEai allows for customized cohort analysis based on a variety of search queries including molecular profiling results, demographic data, diagnostic data, and treatment and survival data. The system also provides data visualization and advanced predictive analytics. The platform is available to members of the Caris Precision Oncology Alliance, a growing collaborative network of cancer centers, as well as to biopharma companies through collaborative relationships.
Paragon Genomics CleanPlex SARS-CoV-2-Related NGS Assays
Paragon Genomics has launched four new coronavirus-related CleanPlex next generation sequencing (NGS) assays. The new panels widen the capabilities of the firm's CleanPlex SARS-CoV-2 Research and Surveillance Panel, which allows researchers to sequence the SARS-CoV-2 genome and obtain accurate nucleic acid-level information on the virus for strain typing, mutation monitoring, and other epidemiological studies.
Paragon's CleanPlex ACE2 & TMPRSS2 Panel identifies genetic mutations in patients that are related to disease susceptibility and severity. The test targets genes affecting the binding affinity and expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine rotease 2 (TMPRSS2). The panel interrogates the entire coding region of ACE2 and TMPRSS2, along with more than 70 curated unique quantitative trait loci that regulate their expression. Paragon noted the panel uses CleanPlex technology's three-hour workflow to produce enriched NGS libraries for all major sequencing platforms.
Paragon's CleanPlex SARS-CoV-2 FLEX Research Panel anticipates increases in SARS-CoV-2 viral mutations and offers extra assurance that mutation detection and genome coverage remain optimal. The FLEX panel specifically focuses on variant analysis and tracking of mutations over time. The test also includes degenerate primers and human RNA primer controls for more confident negative sample calling, especially when viral copies are not present or are at extremely low counts, the firm said.
The company also launched its plated 384 Unique Dual-Indexed PCR Primers for Illumina sequencing of its CleanPlex SARS-CoV-2 NGS panels. The primers will allow additional multiplexing capability so that researchers can simultaneously run up to 3,072 CleanPlex sequencing samples on Illumina NovaSeq instruments.
In anticipation of the upcoming flu season, Paragon is also releasing an early-access edition of the CleanPlex Respiratory Research Panel, which combines assays for SARS-CoV-2, influenza A subtypes H1N1, H1N2, H3N2, and influenza B. The combination panel allows for simultaneous influenza detection with SARS-CoV-2 detection or whole-genome sequencing. The extra sensitivity and additional coverage of the multiplex PCR-based method also works for high-throughput sample pooling and screening strategies, the firm said. Paragon expects to expand the panel to include respiratory syncytial virus and possibly other respiratory viruses in the future.
For more new products and services, please visit the New Products page on our website.